A Phase I/II Study of Repeat Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-Alpha Antagonists

Trial Profile

A Phase I/II Study of Repeat Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-Alpha Antagonists

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2008

At a glance

  • Drugs TgAAC 94 (Primary)
  • Indications Ankylosing spondylitis; Arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Nov 2008 Phase I/II results were reported at the Meeting of the American College of Rheumatology in Oct 2008. Link to ADNM 801127190 added.
    • 12 Jun 2008 Full results were presented during an oral presentation at the Annual European Congress of Rheumatology (EULAR).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top